PROFESSIONAL EDITION

The largest community of pharma leaders

U.S. hospitals to restrict Lilly COVID-19 antibody treatment due to limited supply

(Reuters) – U.S. hospitals, weighing high demand and tight supplies, said they may limit use of a new Eli Lilly and Co LLY.N antibody drug to COVID-19 patients with multiple risk factors for serious illness or to those whose immune systems have not begun to fight the infection. The treatment, bamlanivimab, was given U.S. emergency use authorization (EUA) last week by the Food and Drug Administration for helping newly-diagnosed, high-risk patients avoid hospitalization.

 

Source: https://www.reuters.com/article/us-health-coronavirus-lilly/u-s-hospitals-to-restrict-lilly-covid-19-antibody-treatment-due-to-limited-supply-idUSKBN27X1EU

Recent Articles